Loading...

Robert T O'Donnell

Title(s)Professor, Hematology and Oncology
SchoolUniversity of California, Davis
Phone916-734-3772
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. El-Khoueiry AB, O'Donnell R, Semrad TJ, Mack P, Blanchard S, Bahary N, Jiang Y, Yen Y, Wright J, Chen H, Lenz HJ, Gandara DR. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2018 05; 81(5):957-963. PMID: 29520435.
      View in: PubMed
    2. Barisone GA, O'Donnell RT, Ma Y, Abuhay MW, Lundeberg K, Gowda S, Tuscano JM. A purified, fermented, extract of Triticum aestivum has lymphomacidal activity mediated via natural killer cell activation. PLoS One. 2018; 13(1):e0190860. PMID: 29304125.
      View in: PubMed
    3. Abuhay M, Kato J, Tuscano E, Barisone GA, Sidhu RS, O'Donnell RT, Tuscano JM. The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity. Cancer Immunol Immunother. 2016 10; 65(10):1169-75. PMID: 27506529.
      View in: PubMed
    4. Kong Y, Barisone GA, Abuhay M, O'Donnell RT, Buksh Z, Yousefian F, Tuscano JM. Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7. Leuk Res. 2014 Nov; 38(11):1320-6. PMID: 25241275.
      View in: PubMed
    5. Tuscano JM, Dutia M, Chee K, Brunson A, Reed-Pease C, Abedi M, Welborn J, O'Donnell RT. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol. 2014 May; 165(3):375-81. PMID: 24606326.
      View in: PubMed
    6. Sullivan-Chang L, O'Donnell RT, Tuscano JM. Targeting CD22 in B-cell malignancies: current status and clinical outlook. BioDrugs. 2013 Aug; 27(4):293-304. PMID: 23696252.
      View in: PubMed
    7. Abrams JS, Mooney MM, Zwiebel JA, Korn EL, Friedman SH, Finnigan SR, Schettino PR, Denicoff AM, Kruhm MG, Montello M, Misra RR, Ansher SS, DiPiazza KJ, Souhan EM, Wickerham DL, Giantonio BJ, O'Donnell RT, Sullivan DM, Soto NI, Fleming GF, Prindiville SA, Petryshyn RA, Hautala JA, Grad O, Zuckerman BL, Meyer RM, Yao JC, Baker LA, Buckner JC, Hortobagyi GN, Doroshow JH. Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst. 2013 Jul 03; 105(13):954-9. PMID: 23776198.
      View in: PubMed
    8. Kato J, Satake N, O'Donnell RT, Abuhay M, Lewis C, Tuscano JM. Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia. Leuk Res. 2013 Jan; 37(1):83-8. PMID: 23040543.
      View in: PubMed
    9. Tuscano JM, Kato J, Pearson D, Xiong C, Newell L, Ma Y, Gandara DR, O'Donnell RT. CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy. Cancer Res. 2012 Nov 01; 72(21):5556-65. PMID: 22986740.
      View in: PubMed
    10. Kato J, Li Y, Xiao K, Lee JS, Luo J, Tuscano JM, O'Donnell RT, Lam KS. Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma. Mol Pharm. 2012 Jun 04; 9(6):1727-35. PMID: 22530955.
      View in: PubMed
    11. Martin SM, Churchill E, McKnight H, Mahaffey CM, Ma Y, O'Donnell RT, Tuscano JM. The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner. J Hematol Oncol. 2011 Dec 01; 4:49. PMID: 22128838.
      View in: PubMed
    12. Tuscano JM, Ma Y, Martin SM, Kato J, O'Donnell RT. The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone. Cancer Immunol Immunother. 2011 Jun; 60(6):771-80. PMID: 21347809.
      View in: PubMed
    13. Tuscano JM, Martin SM, Ma Y, Zamboni W, O'Donnell RT. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Clin Cancer Res. 2010 May 15; 16(10):2760-8. PMID: 20460479.
      View in: PubMed
    14. O'Donnell RT, Ma Y, McKnight HC, Pearson D, Tuscano JM. Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts. Cancer Immunol Immunother. 2009 Dec; 58(12):2051-8. PMID: 19437017.
      View in: PubMed
    15. O'Donnell RT, Martin SM, Ma Y, Zamboni WC, Tuscano JM. Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD). Invest New Drugs. 2010 Jun; 28(3):260-7. PMID: 19306119.
      View in: PubMed
    16. O'Donnell RT, Pearson D, McKnight HC, Ma YP, Tuscano JM. Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy. Cancer Immunol Immunother. 2009 Oct; 58(10):1715-22. PMID: 19294384.
      View in: PubMed
    17. O'Donnell RT, Pearson D, McKnight HC, Ma YP, Tuscano JM. Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-hodgkin's lymphoma cells. Leuk Res. 2009 Jul; 33(7):964-9. PMID: 19237192.
      View in: PubMed
    18. Martin SM, O'Donnell RT, Kukis DL, Abbey CK, McKnight H, Sutcliffe JL, Tuscano JM. Imaging and pharmacokinetics of (64)Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin's lymphoma xenografts. Mol Imaging Biol. 2009 Mar-Apr; 11(2):79-87. PMID: 18949521.
      View in: PubMed
    19. Schillaci O, DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, O'Donnell RT, Lamborn KR. Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm. 2007 Aug; 22(4):521-30. PMID: 17803447.
      View in: PubMed
    20. Semrad TJ, O'Donnell R, Wun T, Chew H, Harvey D, Zhou H, White RH. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007 Apr; 106(4):601-8. PMID: 17432710.
      View in: PubMed
    21. Lehmann J, DeNardo GL, Yuan A, Shen S, O'Donnell RT, Richman CM, DeNardo SJ. Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer. Int J Radiat Oncol Biol Phys. 2006 Nov 15; 66(4):1192-8. PMID: 16965873.
      View in: PubMed
    22. O'Donnell RT. Nuclear localizing sequences: an innovative way to improve targeted radiotherapy. J Nucl Med. 2006 May; 47(5):738-9. PMID: 16644741.
      View in: PubMed
    23. Shen S, DeNardo GL, Yuan A, Hartmann-Siantar C, O'Donnell RT, DeNardo SJ. Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody. Cancer Biother Radiopharm. 2005 Dec; 20(6):662-70. PMID: 16398618.
      View in: PubMed
    24. DeNardo SJ, Richman CM, Albrecht H, Burke PA, Natarajan A, Yuan A, Gregg JP, O'Donnell RT, DeNardo GL. Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 2):7187s-7194s. PMID: 16203820.
      View in: PubMed
    25. Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, Tuscano JM, Wun T, Chew HK, Lara PN, Kukis DL, Natarajan A, Meares CF, Lamborn KR, DeNardo GL. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res. 2005 Aug 15; 11(16):5920-7. PMID: 16115934.
      View in: PubMed
    26. Shen S, DeNardo SJ, Richman CM, Yuan A, Siantar CH, O'Donnell RT, Kroger LA, DeNardo GL. Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry. J Nucl Med. 2005 Jun; 46(6):1034-41. PMID: 15937317.
      View in: PubMed
    27. Chen AY, Lee H, Hartman J, Greco C, Ryu JK, O'Donnell R, Boggan J. Secondary supratentorial primitive neuroectodermal tumor following irradiation in a patient with low-grade astrocytoma. AJNR Am J Neuroradiol. 2005 Jan; 26(1):160-2. PMID: 15661719.
      View in: PubMed
    28. Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 2004 Sep-Oct; 10(5):294-300. PMID: 15530258.
      View in: PubMed
    29. DeNardo SJ, DeNardo GL, Yuan A, Richman CM, O'Donnell RT, Lara PN, Kukis DL, Natarajan A, Lamborn KR, Jacobs F, Siantar CL. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 2):3938S-44S. PMID: 14506192.
      View in: PubMed
    30. DeNardo SJ, Yao Z, Lam KS, Song A, Burke PA, Mirick GR, Lamborn KR, O'Donnell RT, DeNardo GL. Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 2):3854S-64S. PMID: 14506183.
      View in: PubMed
    31. DeNardo G, Yuan A, Goldstein D, Richman C, O'Donnell R, Shen S, Hartmann Siantar C, DeNardo S. Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs. Cancer Biother Radiopharm. 2003 Apr; 18(2):231-7. PMID: 12804049.
      View in: PubMed
    32. Tuscano JM, O'Donnell RT, Miers LA, Kroger LA, Kukis DL, Lamborn KR, Tedder TF, DeNardo GL. Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. Blood. 2003 May 01; 101(9):3641-7. PMID: 12511412.
      View in: PubMed
    33. Perez EA, Gandara DR, Edelman MJ, O'Donnell R, Lauder IJ, DeGregorio M. Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies. Cancer Invest. 2003; 21(1):1-6. PMID: 12643003.
      View in: PubMed
    34. Hutchinson K, Kopko PM, Muto KN, Tuscano J, O'Donnell RT, Holland PV, Richman C, Paglieroni TG, Wun T. Early diagnosis and successful treatment of a patient with transfusion-associated GVHD with autologous peripheral blood progenitor cell transplantation. Transfusion. 2002 Dec; 42(12):1567-72. PMID: 12473136.
      View in: PubMed
    35. O'Donnell RT, DeNardo SJ, Miers LA, Lamborn KR, Kukis DL, DeNardo GL, Meyers FJ. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6. Prostate. 2002 Jan 01; 50(1):27-37. PMID: 11757033.
      View in: PubMed
    36. DeNardo GL, DeNardo SJ, Kukis DL, O'Donnell RT, Shen S, Mirick GR, Meares CF. Metabolite production in patients with lymphoma after radiometal-labeled antibody administration. J Nucl Med. 2001 Sep; 42(9):1324-33. PMID: 11535720.
      View in: PubMed
    37. O'Donnell RT, DeNardo SJ, Yuan A, Shen S, Richman CM, Lara PN, Griffith IJ, Goldstein DS, Kukis DL, Martinez GS, Mirick GR, DeNardo GL, Meyers FJ. Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer. Clin Cancer Res. 2001 Jun; 7(6):1561-8. PMID: 11410491.
      View in: PubMed
    38. Lara PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O'Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001 Mar 15; 19(6):1728-33. PMID: 11251003.
      View in: PubMed
    39. DeNardo GL, O'Donnell RT, DeNardo SJ. Radiolabeled anti-lymphoma antibodies. Cancer Chemother Biol Response Modif. 2001; 19:297-308. PMID: 11686019.
      View in: PubMed
    40. DeNardo GL, DeNardo SJ, O'Donnell RT, Kroger LA, Kukis DL, Meares CF, Goldstein DS, Shen S. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma. Clin Lymphoma. 2000 Sep; 1(2):118-26. PMID: 11707820.
      View in: PubMed
    41. O'Donnell RT, Shen S, Denardo SJ, Wun T, Kukis DL, Goldstein DS, Denardo GL. A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. Anticancer Res. 2000 Sep-Oct; 20(5C):3647-55. PMID: 11268433.
      View in: PubMed
    42. O'Donnell RT, DeNardo SJ, DeNardo GL, Miers L, Lamborn KR, Kukis DL, Meyers FJ. Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice. Prostate. 2000 Aug 01; 44(3):187-92. PMID: 10906734.
      View in: PubMed
    43. DeNardo GL, O'Donnell RT, Shen S, Kroger LA, Yuan A, Meares CF, Kukis DL, DeNardo SJ. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. J Nucl Med. 2000 May; 41(5):952-8. PMID: 10809213.
      View in: PubMed
    44. DeNardo SJ, Burke PA, Leigh BR, O'Donnell RT, Miers LA, Kroger LA, Goodman SL, Matzku S, Jonczyk A, Lamborn KR, DeNardo GL. Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. Cancer Biother Radiopharm. 2000 Feb; 15(1):71-9. PMID: 10740655.
      View in: PubMed
    45. Shen S, DeNardo GL, Sgouros G, O'Donnell RT, DeNardo SJ. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med. 1999 Dec; 40(12):2102-6. PMID: 10616892.
      View in: PubMed
    46. O'Donnell RT, DeNardo GL, Kukis DL, Lamborn KR, Shen S, Yuan A, Goldstein DS, Carr CE, Mirick GR, DeNardo SJ. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. J Nucl Med. 1999 Dec; 40(12):2014-20. PMID: 10616879.
      View in: PubMed
    47. Kukis DL, DeNardo SJ, Mills SL, Shen S, O'Donnell RT, DeNardo GL. Stability of monoclonal antibodies, Lym-1 and ChL6, and 2IT-BAD-Lym-1 immunoconjugate with ultra freezer storage. Cancer Biother Radiopharm. 1999 Oct; 14(5):363-9. PMID: 10850321.
      View in: PubMed
    48. Richman CM, DeNardo SJ, O'Donnell RT, Goldstein DS, Shen S, Kukis DL, Kroger LA, Yuan A, Boniface GR, Griffith IJ, DeNardo GL. Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A. Clin Cancer Res. 1999 Oct; 5(10 Suppl):3243s-3248s. PMID: 10541370.
      View in: PubMed
    49. O'Donnell RT, DeNardo GL, Kukis DL, Lamborn KR, Shen S, Yuan A, Goldstein DS, Mirick GR, DeNardo SJ. 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma. Clin Cancer Res. 1999 Oct; 5(10 Suppl):3330s-3336s. PMID: 10541382.
      View in: PubMed
    50. DeNardo GL, O'Donnell RT, Kroger LA, Richman CM, Goldstein DS, Shen S, DeNardo SJ. Strategies for developing effective radioimmunotherapy for solid tumors. Clin Cancer Res. 1999 Oct; 5(10 Suppl):3219s-3223s. PMID: 10541367.
      View in: PubMed
    51. Mirick GR, O'Donnell RT, DeNardo SJ, Shen S, Meares CF, DeNardo GL. Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients. Nucl Med Biol. 1999 Oct; 26(7):841-5. PMID: 10628566.
      View in: PubMed
    52. O'Donnell RT, Leigh BR, Christensen SD, Goldstein DS, Kukis DL, Shen S, Yuan A, DeNardo DA, Kroger LA, DeNardo GL. Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma. Cancer Biother Radiopharm. 1999 Jun; 14(3):167-76. PMID: 10850301.
      View in: PubMed
    53. Leigh BR, Burke PA, Hong AM, O'Donnell RT, Howell LP, Miers LA, DeNardo GL, DeNardo SJ. Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapy. Cancer Biother Radiopharm. 1999 Apr; 14(2):113-9. PMID: 10850294.
      View in: PubMed
    54. DeNardo GL, O'Donnell RT, Rose LM, Mirick GR, Kroger LA, DeNardo SJ. Milestones in the development of Lym-1 therapy. Hybridoma. 1999 Feb; 18(1):1-11. PMID: 10211782.
      View in: PubMed
    55. Kukis DL, DeNardo SJ, DeNardo GL, O'Donnell RT, Meares CF. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates. J Nucl Med. 1998 Dec; 39(12):2105-10. PMID: 9867151.
      View in: PubMed
    56. O'Donnell RT, DeNardo SJ, Miers LA, Kukis DL, Mirick GR, Kroger LA, DeNardo GL. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts. Cancer Biother Radiopharm. 1998 Oct; 13(5):351-61. PMID: 10851425.
      View in: PubMed
    57. O'Donnell RT, DeNardo SJ, Shi XB, Mirick GR, DeNardo GL, Kroger LA, Meyers FJ. L6 monoclonal antibody binds prostate cancer. Prostate. 1998 Oct 01; 37(2):91-7. PMID: 9759703.
      View in: PubMed
    58. DeNardo GL, O'Donnell RT, Oldham RK, DeNardo SJ. A revolution in the treatment of non-Hodgkin's lymphoma. Cancer Biother Radiopharm. 1998 Aug; 13(4):213-23. PMID: 10850358.
      View in: PubMed
    59. Denardo GL, Denardo SJ, Kukis DL, O'Donnell RT, Shen S, Goldstein DS, Kroger LA, Salako Q, Denardo DA, Mirick GR, Mausner LF, Srivastava SC, Meares CF. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. Anticancer Res. 1998 Jul-Aug; 18(4B):2779-88. PMID: 9713461.
      View in: PubMed
    60. Shen S, DeNardo GL, Jones TD, Wilder RB, O'Donnell RT, DeNardo SJ. A preliminary cell kinetics model of thrombocytopenia after radioimmunotherapy. J Nucl Med. 1998 Jul; 39(7):1223-9. PMID: 9669399.
      View in: PubMed
    61. Salako QA, O'Donnell RT, DeNardo SJ. Effects of radiolysis on yttrium-90-labeled Lym-1 antibody preparations. J Nucl Med. 1998 Apr; 39(4):667-70. PMID: 9544679.
      View in: PubMed
    62. DeNardo DA, DeNardo GL, O'Donnell RT, Lim SM, Shen S, Yuan A, DeNardo SJ. Imaging for improved prediction of myelotoxicity after radioimmunotherapy. Cancer. 1997 Dec 15; 80(12 Suppl):2558-66. PMID: 9406710.
      View in: PubMed
    63. Shen S, DeNardo GL, O'Donnell RT, Yuan A, DeNardo DA, DeNardo SJ. Impact of splenomegaly on therapeutic response and I-131-LYM-1 dosimetry in patients with B-lymphocytic malignancies. Cancer. 1997 Dec 15; 80(12 Suppl):2553-7. PMID: 9406709.
      View in: PubMed
    64. DeNardo GL, Kukis DL, DeNardo SJ, Shen S, Mausner LF, O'Donnell RT, Lamborn KR, Meyers FJ, Srivastava SC, Miers LA. Enhancement of 67Cu-2IT-BAT-LYM-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2. Cancer. 1997 Dec 15; 80(12 Suppl):2576-82. PMID: 9406712.
      View in: PubMed
    65. DeNardo SJ, Kroger LA, Lamborn KR, Miers LA, O'Donnell RT, Kukis DL, Richman CM, DeNardo GL. Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma. Cancer. 1997 Dec 15; 80(12 Suppl):2583-90. PMID: 9406713.
      View in: PubMed
    66. Richman CM, Schuermann TC, Wun T, Malik R, O'Donnell RT, DeNardo GL, DeNardo SJ. Peripheral blood stem cell mobilization for hematopoietic support of radioimmunotherapy in patients with breast carcinoma. Cancer. 1997 Dec 15; 80(12 Suppl):2728-32. PMID: 9406731.
      View in: PubMed
    67. Lim S, DeNardo GL, DeNardo DA, O'Donnell RT, Yuan A, DeNardo SJ. Prediction of myelotoxicity using semi-quantitative marrow image scores. J Nucl Med. 1997 Nov; 38(11):1749-53. PMID: 9374345.
      View in: PubMed
    68. Lim SM, DeNardo GL, DeNardo DA, Shen S, Yuan A, O'Donnell RT, DeNardo SJ. Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources. J Nucl Med. 1997 Sep; 38(9):1374-8. PMID: 9293790.
      View in: PubMed
    69. DeNardo SJ, Kramer EL, O'Donnell RT, Richman CM, Salako QA, Shen S, Noz M, Glenn SD, Ceriani RL, DeNardo GL. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. J Nucl Med. 1997 Aug; 38(8):1180-5. PMID: 9255145.
      View in: PubMed
    70. Shen S, DeNardo GL, Macey DJ, O'Donnell RT, Yuan A, DeNardo DA, DeNardo SJ. Practical determination of organ S values for individual patients for therapy. Nucl Med Biol. 1997 Jul; 24(5):447-9. PMID: 9290081.
      View in: PubMed
    71. Denardo SJ, O'Grady LF, Richman CM, Goldstein DS, O'Donnell RT, Denardo DA, Kroger LA, Lamborn KR, Hellström KE, Hellström I, Denardo GL. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res. 1997 May-Jun; 17(3B):1745-51. PMID: 9179228.
      View in: PubMed
    72. DeNardo SJ, Kukis DL, Kroger LA, O'Donnell RT, Lamborn KR, Miers LA, DeNardo DG, Meares CF, DeNardo GL. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci U S A. 1997 Apr 15; 94(8):4000-4. PMID: 9108094.
      View in: PubMed
    73. Edelman MJ, O'Donnell RT, Meadows I. Treatment of refractory large granular lymphocytic leukemia with 2-chlorodeoxyadenosine. Am J Hematol. 1997 Apr; 54(4):329-31. PMID: 9092691.
      View in: PubMed
    74. DeNardo SJ, O'Donnell RT, DeNardo GL. Potential use of amino acid cocktails to reduce renal tubular reabsorption of radioconjugates. J Nucl Med. 1996 May; 37(5):837-8. PMID: 8965156.
      View in: PubMed
    75. DeNardo GL, Mirick GR, Kroger LA, O'Donnell RT, Meares CF, DeNardo SJ. Antibody responses to macrocycles in lymphoma. J Nucl Med. 1996 Mar; 37(3):451-6. PMID: 8772643.
      View in: PubMed
    76. Lengle SJ, Hecht ST, Link DP, O'Donnell R. Palliative embolization of fibrosarcoma for control of tumor-induced hypoglycemia. Cardiovasc Intervent Radiol. 1995 Jul-Aug; 18(4):255-8. PMID: 8581908.
      View in: PubMed
    77. O'Donnell RT, Dea G, Meyers FJ. A phase II trial of concomitant interferon-alpha-2b and granulocyte-macrophage colony-stimulating factor in patients with advanced renal cell carcinoma. J Immunother Emphasis Tumor Immunol. 1995 Jan; 17(1):58-61. PMID: 7728306.
      View in: PubMed
    78. Welborn JL, O'Donnell R, Hsieh T, Eatherton J, Aspry K. Vincristine for thrombocytopenic purpura. Lancet. 1991 Feb 09; 337(8737):377-8. PMID: 1671287.
      View in: PubMed
    79. O'Donnell RT, Andersen BR. Isolation of canine neutrophil plasma membranes. J Leukoc Biol. 1985 Sep; 38(3):353-68. PMID: 2993461.
      View in: PubMed
    80. O'Donnell RT, Andersen BR. Canine neutrophil plasma membrane markers. Biochim Biophys Acta. 1985 Apr 11; 814(2):307-12. PMID: 2983765.
      View in: PubMed
    81. O'Donnell RT, Andersen BR. Characterization of canine neutrophil granules. Infect Immun. 1982 Oct; 38(1):351-9. PMID: 6292095.
      View in: PubMed
    82. Jensen WE, O'Donnell RT, Rosenberg IH, Karlin DA, Jones RD. Gaseous contaminants in sterilized evacuated blood collection tubes. Clin Chem. 1982 Jun; 28(6):1406. PMID: 7074960.
      View in: PubMed
    83. Karlin DA, O'Donnell RT, Jensen WE. Effect of dioctyl sodium sulfosuccinate feeding on rat colorectal 1,2-dimethylhydrazine carcinogenesis. J Natl Cancer Inst. 1980 Apr; 64(4):791-3. PMID: 6154162.
      View in: PubMed